TCON — TRACON Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $4.46m
- -$4.10m
- $12.05m
- 34
- 75
- 62
- 58
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 1.21 | ||
| Price to Sales | 0.37 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -76.99% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 0.35 | n/a | 12.04 | n/a | 1.75 | 32.05% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize products in the United States. The Company’s clinical-stage oncology product candidate is TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors and YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody. TRC102 is a small molecule in clinical development to reverse resistance to specific chemotherapeutics by inhibiting DNA base excision repair (BER). Its clinical-stage product candidate, Envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma.
Directors
- Charles Theuer PRE (57)
- Scott Brown CFO (40)
- Mark Wiggins OTH (65)
- Carol Lam DRC
- Lisa Johnson-pratt IND (57)
- William LaRue IND (70)
- Martin Mattingly IND (64)
- Saundra Pelletier IND (51)
- J. Rainer Twiford IND (68)
- Stephen Worland IND (63)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 28th, 2004
- Public Since
- January 30th, 2015
- No. of Shareholders
- 101
- No. of Employees
- 17
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 2,275,226
- Address
- 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO, 92122
- Web
- https://www.traconpharma.com/
- Phone
- +1 8585500780
- Auditors
- Ernst & Young LLP
Upcoming Events for TCON
Q2 2024 TRACON Pharmaceuticals Inc Earnings Release
Similar to TCON
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Aadi Bioscience
NASDAQ Capital Market
Acasti Pharma
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Aptorum
NASDAQ Capital Market
FAQ
What is the TRACON Pharmaceuticals share price?
As of Today at 19:23 UTC, shares in TRACON Pharmaceuticals are trading at $1.96. This share price information is delayed by 15 minutes.
How has the TRACON Pharmaceuticals share price performed this year?
Shares in TRACON Pharmaceuticals last closed at $1.96 and the price had moved by -94.49% over the past 365 days. In terms of relative price strength the TRACON Pharmaceuticals share price has underperformed the S&P500 Index by -95.42% over the past year.
What are the analyst and broker recommendations for TRACON Pharmaceuticals?
The overall consensus recommendation for TRACON Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the TRACON Pharmaceuticals dividend yield?
TRACON Pharmaceuticals does not currently pay a dividend.
Does TRACON Pharmaceuticals pay a dividend?
TRACON Pharmaceuticals does not currently pay a dividend.
When does TRACON Pharmaceuticals next pay dividends?
TRACON Pharmaceuticals does not currently pay a dividend.
How do I buy TRACON Pharmaceuticals shares?
To buy shares in TRACON Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of TRACON Pharmaceuticals?
As of the previous close price of $1.96, shares in TRACON Pharmaceuticals had a market capitalisation of $4.46m.
Where are TRACON Pharmaceuticals shares listed?
Here are the trading details for TRACON Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: TCON
What kind of share is TRACON Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum TRACON Pharmaceuticals is currently classified as a Turnaround. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a TRACON Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in TRACON Pharmaceuticals is $37.50. That is 1813.27% above the last closing price of $1.96.
Analysts covering TRACON Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$4.62 for the next financial year.
What is the trend in the TRACON Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like TRACON Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -46.94%.
As of the last closing price of $1.96, shares in TRACON Pharmaceuticals were trading -56.21% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the TRACON Pharmaceuticals PE Ratio?
The TRACON Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.96.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of TRACON Pharmaceuticals?
TRACON Pharmaceuticals' management team is headed by:
- Charles Theuer - PRE
- Scott Brown - CFO
- Mark Wiggins - OTH
- Carol Lam - DRC
- Lisa Johnson-pratt - IND
- William LaRue - IND
- Martin Mattingly - IND
- Saundra Pelletier - IND
- J. Rainer Twiford - IND
- Stephen Worland - IND